Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) Target Price at $6.00

Context Therapeutics Inc. (NASDAQ:CNTX) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $6.00.

Several analysts have recently weighed in on CNTX shares. HC Wainwright upped their price objective on Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Cantor Fitzgerald started coverage on shares of Context Therapeutics in a report on Thursday, October 2nd. They issued an “overweight” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Context Therapeutics in a research note on Wednesday, October 8th. Jones Trading assumed coverage on shares of Context Therapeutics in a research note on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. Finally, Guggenheim started coverage on shares of Context Therapeutics in a report on Thursday, September 18th. They set a “buy” rating and a $5.00 target price for the company.

Context Therapeutics Price Performance

NASDAQ CNTX opened at $1.57 on Monday. Context Therapeutics has a 12 month low of $0.49 and a 12 month high of $2.00. The firm has a market capitalization of $144.25 million, a PE ratio of -6.54 and a beta of 1.91. The company’s 50 day simple moving average is $1.22 and its 200 day simple moving average is $1.03.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.01). Sell-side analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Context Therapeutics during the 3rd quarter worth about $100,000. Finally, Clear Harbor Asset Management LLC lifted its stake in Context Therapeutics by 60.5% during the third quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after buying an additional 35,000 shares in the last quarter. 14.03% of the stock is currently owned by institutional investors and hedge funds.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.